Gold prices slip lower; consolidating after recent gains
Chicago-based Tempus AI , Inc. (NASDAQ:TEM) saw a notable transaction involving its Executive Vice President and Chief Administrative & Legal Officer, Erik Phelps. On May 20, 2025, Phelps sold a total of 8,415 shares of Class A Common Stock, with the sale yielding approximately $531,918. The shares were sold at prices ranging from $63.21 to $63.70 per share.
This transaction was part of a mandatory "sell to cover" arrangement, designed to meet statutory tax withholding obligations related to the vesting of restricted stock units. Following the sale, Phelps holds 149,096 shares directly. The timing of the sale coincides with a challenging period for the stock, which has declined 9.53% over the past week. InvestingPro subscribers can access 7 additional key insights about TEM’s financial health and market position through the comprehensive Pro Research Report, available exclusively on the platform.
In other recent news, Tempus AI Inc. reported a significant 75.4% year-over-year increase in first-quarter revenue, reaching $255.7 million, surpassing analyst expectations of $248.5 million. The company’s earnings per share were slightly better than anticipated, at -$0.24 compared to the forecast of -$0.26. Tempus AI also announced a strategic partnership with Verastem (NASDAQ:VSTM) Oncology to develop a companion diagnostic test for recurrent low-grade serous ovarian cancer, leveraging Tempus’s xT CDx assay. Additionally, Tempus AI has entered a multi-year collaboration with Boehringer Ingelheim to enhance cancer treatment research, integrating its AI-powered platform with Boehringer’s oncology pipeline.
Morgan Stanley (NYSE:MS) raised its price target for Tempus AI to $65 from $60, maintaining an Overweight rating, following the company’s strong first-quarter performance and a significant contract with AstraZeneca (NASDAQ:AZN) and the Pathos foundation. This $200 million contract is expected to contribute to Tempus AI’s medium-term growth. The company increased its full-year 2025 revenue guidance to $1.25 billion, projecting an 80% year-over-year growth. Tempus AI continues to invest in AI and data infrastructure, aiming to develop the world’s largest foundation model in oncology. These developments underscore Tempus AI’s commitment to advancing precision medicine and expanding its partnerships in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.